AI Workflow Automation Pharma RnD

Published by Masonsoft Technology Ltd in March 2026, this strategic paper sets out the case for pharmaceutical and life sciences R&D organisations beginning their AI programme with administrative workflow improvements rather than platform-level transformation. It argues that between 25 and 40% of scientific and regulatory professional time is consumed by document management and administrative coordination, and that in a sector where each month of accelerated development timeline carries very large commercial value, this overhead has financial consequences that few other industries face. The paper examines six workflow areas where AI delivers measurable first-year returns: scientific literature review, regulatory document preparation, clinical trial data management, GxP compliance, intellectual property and patent workflows, and supply chain and CMO management. Reported first-year returns of 110 to 230% are presented in a summary evidence table across large pharmaceutical companies, biotechs, contract research organisations, and medical device developers. A five-step prioritisation framework, built around the sector's existing computer system validation discipline and GxP data integrity requirements, guides organisations from pipeline bottleneck analysis through validation assessment, audit trail design, metric definition, and governed deployment. A final section addresses four concerns: GxP validation requirements, scientist trust, regulatory agency acceptance, and proprietary data security.